[go: up one dir, main page]

PE20091669A1 - Benzofuropirimidinonas - Google Patents

Benzofuropirimidinonas

Info

Publication number
PE20091669A1
PE20091669A1 PE2008002147A PE2008002147A PE20091669A1 PE 20091669 A1 PE20091669 A1 PE 20091669A1 PE 2008002147 A PE2008002147 A PE 2008002147A PE 2008002147 A PE2008002147 A PE 2008002147A PE 20091669 A1 PE20091669 A1 PE 20091669A1
Authority
PE
Peru
Prior art keywords
benzofide
ilmethyl
pyrrolidin
pyrimidin
halo
Prior art date
Application number
PE2008002147A
Other languages
English (en)
Inventor
S David Brown
Hongwang Du
Maurizio Franzini
Adam Antoni Galan
Ping Huang
Patrick Kearney
Moon Hwan Kim
Elena S Koltun
Steven James Richards
Amy L Tsuhako
Cristiana A Zaharia
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091669(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20091669A1 publication Critical patent/PE20091669A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 ES H, ALQUILO; R2 ES AMINOCARBONILALQUILAMINOALQUILO, CICLOALQUILAMINOALQUILO, ARILALQUILO, ENTRE OTROS; R3a ES HALO, ALQUILO, -NO2, ALCOXI, ALQUINILO SUSTITUIDO O NO, ALCOXICARBONILALQUILO, ENTRE OTROS; R3b, R3c Y R3d SON CADA UNO H, -OH, ALCOXILO, HALO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 8-BROMO-2-(PIRROLIDIN-1-ILMETIL)[1]BENZOFURO[3,2-d]PIRIMIDIN-4(3H)-ONA; 8-CLORO-2-(PIRROLIDIN-1-ILMETIL)[1]BENZOFURO[3,2-d]PIRIMIDIN-4(3H)-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE PROTEINA QUINASA UTILES EN EL TRATAMIENTO DE CANCER
PE2008002147A 2007-12-21 2008-12-19 Benzofuropirimidinonas PE20091669A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US890707P 2007-12-21 2007-12-21
US7097108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
PE20091669A1 true PE20091669A1 (es) 2009-12-06

Family

ID=40383673

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002147A PE20091669A1 (es) 2007-12-21 2008-12-19 Benzofuropirimidinonas

Country Status (20)

Country Link
US (1) US20090247559A1 (es)
EP (1) EP2097419B1 (es)
JP (1) JP2011507908A (es)
KR (1) KR20100098714A (es)
CN (1) CN101965351A (es)
AR (1) AR069869A1 (es)
AT (1) ATE510839T1 (es)
AU (1) AU2008345560A1 (es)
BR (1) BRPI0821573A2 (es)
CA (1) CA2712358A1 (es)
CL (1) CL2008003873A1 (es)
CO (1) CO6321258A2 (es)
EA (1) EA019785B1 (es)
IL (1) IL206416A0 (es)
MX (1) MX2010006799A (es)
NZ (1) NZ586936A (es)
PE (1) PE20091669A1 (es)
TW (1) TW200930375A (es)
WO (1) WO2009086264A1 (es)
ZA (1) ZA201004243B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
MY160526A (en) 2008-12-22 2017-03-15 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
WO2012039448A1 (ja) * 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
CN102875558A (zh) * 2012-11-05 2013-01-16 贵州大学 2-氯-4-取代-8-硝基苯并呋喃[3,2-d]嘧啶类化合物及其制备方法和用途
CN103044370A (zh) * 2012-12-28 2013-04-17 山东邹平大展新材料有限公司 一种5-（哌嗪-1-基）苯并呋喃-2-甲酰胺的制备方法
CN104045642B (zh) * 2013-03-14 2016-08-24 上海医药工业研究院 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2015115355A1 (ja) 2014-01-31 2015-08-06 カルナバイオサイエンス株式会社 抗がん剤組成物
CN106255679B (zh) * 2014-02-27 2019-09-06 默克专利有限公司 用作nav通道抑制剂的杂环化合物及其用途
WO2015152319A1 (ja) * 2014-04-02 2015-10-08 株式会社 三和化学研究所 ５，７－無置換－ピラゾロ［１，５－ａ］ピリミジン－６－カルボン酸の製造方法
KR101837565B1 (ko) 2014-08-06 2018-03-12 삼성에스디아이 주식회사 유기 화합물, 유기 광전자 소자 및 표시 장치
JP6840931B2 (ja) * 2015-03-09 2021-03-10 東ソー株式会社 縮環芳香族化合物の製造方法
EP3538523B1 (en) 2016-11-08 2021-05-19 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
CN111689947B (zh) * 2019-03-13 2023-07-14 鲁南制药集团股份有限公司 替加氟-l-脯氨酸共晶体及其制备方法
CA3164707A1 (en) * 2020-02-03 2021-08-12 Ana Maria Garcia Collazo Combination therapy for treating mps1
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
IL301866A (en) * 2020-10-05 2023-06-01 Japan Tobacco Inc Tetrahydrobenzofurodiazepinone compounds and their remote applications
WO2022194799A1 (de) 2021-03-18 2022-09-22 Merck Patent Gmbh Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen
KR20240149429A (ko) * 2022-02-16 2024-10-14 듀크 스트리트 바이오 리미티드 약학적 화합물
CN116731025B (zh) * 2023-05-24 2025-06-24 曲阜师范大学 一种具有2-芳基苯并呋喃并[2,3-d]嘧啶酮类结构的荧光材料及其制备方法和应用
CN120114459B (zh) * 2025-05-14 2025-07-29 南京工业大学 苯并呋喃嘧啶酮或苯并噻吩嘧啶酮类化合物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO2002051849A1 (en) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
CA2444598A1 (en) * 2001-04-20 2003-10-31 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of gsk-3
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
WO2006023381A1 (en) * 2004-08-16 2006-03-02 Taigen Biotechnology Pyrimidinone compounds
AU2005303893A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
EP1776982A1 (en) 2005-10-18 2007-04-25 Argenta Discovery Limited Pyrimidine compounds as histamine modulators

Also Published As

Publication number Publication date
IL206416A0 (en) 2010-12-30
EA201070786A1 (ru) 2011-02-28
BRPI0821573A2 (pt) 2016-08-09
TW200930375A (en) 2009-07-16
US20090247559A1 (en) 2009-10-01
KR20100098714A (ko) 2010-09-08
WO2009086264A1 (en) 2009-07-09
AU2008345560A1 (en) 2009-07-09
ATE510839T1 (de) 2011-06-15
JP2011507908A (ja) 2011-03-10
CL2008003873A1 (es) 2009-06-26
ZA201004243B (en) 2011-03-30
EA019785B1 (ru) 2014-06-30
AR069869A1 (es) 2010-02-24
CN101965351A (zh) 2011-02-02
EP2097419B1 (en) 2011-05-25
NZ586936A (en) 2012-07-27
CO6321258A2 (es) 2011-09-20
MX2010006799A (es) 2010-10-05
EP2097419A1 (en) 2009-09-09
CA2712358A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
PE20091669A1 (es) Benzofuropirimidinonas
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
BRPI0611095B8 (pt) compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos
PE20070752A1 (es) Triazolopiridazinas como moduladores de quinasa
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
ECSP099400A (es) Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa
MX340490B (es) Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
PE20120493A1 (es) Pirimidinonas como inhibidores de pi3k
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
MX2010001821A (es) Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
CL2008002687A1 (es) Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20080893A1 (es) Triazoles biciclicos como moduladores de la proteina cinasa
CR9650A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
AR042042A1 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
PE20110403A1 (es) Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer
JO2885B1 (en) Protein kinase inhibitors
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
GEP20104884B (en) Monocyclic heterocycles as kinase inhibitors
NZ599815A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PE20110834A1 (es) DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EA200600064A1 (ru) Производные тиенопиридона как ингибиторы киназ
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.

Legal Events

Date Code Title Description
FC Refusal